Summary | |
---|---|
Symbol | HPGD |
Name | hydroxyprostaglandin dehydrogenase 15-(NAD) |
Aliases | SDR36C1; short chain dehydrogenase/reductase family 36C, member 1; 15-PGDH; PGDH1; PHOAR1; NAD+-dependent 15 ...... |
Chromosomal Location | 4q34-q35 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway |
Subcellular Location | Cytoplasm. |
Domain |
PF00106 short chain dehydrogenase |
Function |
Prostaglandin inactivation. Contributes to the regulation of events that are under the control of prostaglandin levels. Catalyzes the NAD-dependent dehydrogenation of lipoxin A4 to form 15-oxo-lipoxin A4. Inhibits in vivo proliferation of colon cancer cells. |
Biological Process |
GO:0006631 fatty acid metabolic process GO:0006690 icosanoid metabolic process GO:0006692 prostanoid metabolic process GO:0006693 prostaglandin metabolic process GO:0007178 transmembrane receptor protein serine/threonine kinase signaling pathway GO:0007179 transforming growth factor beta receptor signaling pathway GO:0007292 female gamete generation GO:0007565 female pregnancy GO:0007567 parturition GO:0019372 lipoxygenase pathway GO:0030728 ovulation GO:0033559 unsaturated fatty acid metabolic process GO:0044706 multi-multicellular organism process GO:0045786 negative regulation of cell cycle GO:0048514 blood vessel morphogenesis GO:0048844 artery morphogenesis GO:0060840 artery development GO:0070493 thrombin receptor signaling pathway GO:0071559 response to transforming growth factor beta GO:0071560 cellular response to transforming growth factor beta stimulus GO:0097070 ductus arteriosus closure GO:1901568 fatty acid derivative metabolic process GO:2001300 lipoxin metabolic process |
Molecular Function |
GO:0004953 icosanoid receptor activity GO:0004954 prostanoid receptor activity GO:0004955 prostaglandin receptor activity GO:0004957 prostaglandin E receptor activity GO:0016404 15-hydroxyprostaglandin dehydrogenase (NAD+) activity GO:0016614 oxidoreductase activity, acting on CH-OH group of donors GO:0016616 oxidoreductase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor GO:0048037 cofactor binding GO:0050662 coenzyme binding GO:0051287 NAD binding GO:0070403 NAD+ binding |
Cellular Component |
GO:0016323 basolateral plasma membrane |
KEGG | - |
Reactome |
R-HSA-2142753: Arachidonic acid metabolism R-HSA-1430728: Metabolism R-HSA-556833: Metabolism of lipids and lipoproteins R-HSA-2142700: Synthesis of Lipoxins (LX) R-HSA-2162123: Synthesis of Prostaglandins (PG) and Thromboxanes (TX) |
Summary | |
---|---|
Symbol | HPGD |
Name | hydroxyprostaglandin dehydrogenase 15-(NAD) |
Aliases | SDR36C1; short chain dehydrogenase/reductase family 36C, member 1; 15-PGDH; PGDH1; PHOAR1; NAD+-dependent 15 ...... |
Chromosomal Location | 4q34-q35 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Literatures that report relations between HPGD and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells. |
Literatures describing the relation between HPGD and anti-tumor immunity in human cancer.
|
Summary | |
---|---|
Symbol | HPGD |
Name | hydroxyprostaglandin dehydrogenase 15-(NAD) |
Aliases | SDR36C1; short chain dehydrogenase/reductase family 36C, member 1; 15-PGDH; PGDH1; PHOAR1; NAD+-dependent 15 ...... |
Chromosomal Location | 4q34-q35 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets. |
> High-throughput Screening
[ TOP ]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Statistical results of HPGD in screening data sets for detecting immune reponses.
|
Summary | |
---|---|
Symbol | HPGD |
Name | hydroxyprostaglandin dehydrogenase 15-(NAD) |
Aliases | SDR36C1; short chain dehydrogenase/reductase family 36C, member 1; 15-PGDH; PGDH1; PHOAR1; NAD+-dependent 15 ...... |
Chromosomal Location | 4q34-q35 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders |
Points in the above scatter plot represent the expression difference of HPGD in various data sets.
|
Points in the above scatter plot represent the mutation difference of HPGD in various data sets.
|
Summary | |
---|---|
Symbol | HPGD |
Name | hydroxyprostaglandin dehydrogenase 15-(NAD) |
Aliases | SDR36C1; short chain dehydrogenase/reductase family 36C, member 1; 15-PGDH; PGDH1; PHOAR1; NAD+-dependent 15 ...... |
Chromosomal Location | 4q34-q35 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HPGD. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene. |
Summary | |
---|---|
Symbol | HPGD |
Name | hydroxyprostaglandin dehydrogenase 15-(NAD) |
Aliases | SDR36C1; short chain dehydrogenase/reductase family 36C, member 1; 15-PGDH; PGDH1; PHOAR1; NAD+-dependent 15 ...... |
Chromosomal Location | 4q34-q35 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HPGD. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HPGD. > Immunoinhibitor > Immunostimulator > MHC molecule |
Summary | |
---|---|
Symbol | HPGD |
Name | hydroxyprostaglandin dehydrogenase 15-(NAD) |
Aliases | SDR36C1; short chain dehydrogenase/reductase family 36C, member 1; 15-PGDH; PGDH1; PHOAR1; NAD+-dependent 15 ...... |
Chromosomal Location | 4q34-q35 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HPGD. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor |
Summary | |
---|---|
Symbol | HPGD |
Name | hydroxyprostaglandin dehydrogenase 15-(NAD) |
Aliases | SDR36C1; short chain dehydrogenase/reductase family 36C, member 1; 15-PGDH; PGDH1; PHOAR1; NAD+-dependent 15 ...... |
Chromosomal Location | 4q34-q35 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Distribution of HPGD expression across immune and molecular subtypes. > Immune subtype > Molecular subtype |
Summary | |
---|---|
Symbol | HPGD |
Name | hydroxyprostaglandin dehydrogenase 15-(NAD) |
Aliases | SDR36C1; short chain dehydrogenase/reductase family 36C, member 1; 15-PGDH; PGDH1; PHOAR1; NAD+-dependent 15 ...... |
Chromosomal Location | 4q34-q35 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content |
Associations between HPGD and clinical features. > Overall survival analysis > Cancer stage > Tumor grade |
Summary | |
---|---|
Symbol | HPGD |
Name | hydroxyprostaglandin dehydrogenase 15-(NAD) |
Aliases | SDR36C1; short chain dehydrogenase/reductase family 36C, member 1; 15-PGDH; PGDH1; PHOAR1; NAD+-dependent 15 ...... |
Chromosomal Location | 4q34-q35 |
External Links | HGNC, NCBI, Ensembl, Uniprot, GeneCards |
Content | Drugs targeting HPGD collected from DrugBank database. |
Details on drugs targeting HPGD.
|